Search company, investor...

Founded Year



Series F | Alive

Total Raised




Last Raised

$100M | 10 mos ago



Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Benchling

Benchling is an informatics platform to accelerate, measure, and forecast R&D from discovery through bioprocessing.

Benchling Headquarters Location

680 Folsom St. 8th Floor

San Francisco, California, 94107,

United States


ESPs containing Benchling

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

Companies in this space develop software to help streamline drug discovery, preclinical, and other R&D laboratory operations. Startups in this market offer platforms that include electronic lab notebooks (ELNs) and lab information management systems (LIMS).

Benchling named as Leader among 10 other companies, including Synthace, TeselaGen, and Sapio Sciences.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Benchling's Products & Differentiation

See Benchling's products and how their products differentiate from alternatives and competitors

  • Benchling R&D Cloud

    A unified suite of R&D applications, built on a trusted, secure cloud platform, to accelerate innovation in the life sciences. This is our flagship offering and comes in multiple configurations for companies of all sizes and R&D business requirements. (note: it consists of a multitude applications that serve different functions, but we tend to market this as one 'product', since the value comes from using them together).

Expert Collections containing Benchling

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Benchling is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,187 items


Future Unicorns 2019

50 items


Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Advanced Manufacturing

2,427 items

Companies focused on the technologies to increase manufacturing productivity, ranging from automation & robotics to AR/VR to factory analytics & AI, plus many more.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Benchling Patents

Benchling has filed 1 patent.

The 3 most popular patent topics include:

  • Cloud storage
  • Database management systems
  • File hosting
patents chart

Application Date

Grant Date


Related Topics




Cloud storage, Rotating disc computer storage media, Molecular biology, Database management systems, File hosting


Application Date


Grant Date



Related Topics

Cloud storage, Rotating disc computer storage media, Molecular biology, Database management systems, File hosting



Latest Benchling News

Benchling Launches the First Complete Solution for RNA R&D to Accelerate mRNA and RNA Therapeutics Development

Sep 8, 2022

Search jobs 08-Sep-2022 Benchling Launches the First Complete Solution for RNA R&D to Accelerate mRNA and RNA Therapeutics Development Benchling Launches the First Complete Solution for RNA R&D to Accelerate mRNA and RNA Therapeutics Development   Nearly half (44%) of top 50 biopharma companies are now involved in RNA work sparking new demand for tools purpose built for the full spectrum of RNA R&D   SAN FRANCISCO, September 7, 2022 — Benchling , the R&D Cloud powering the biotechnology industry, today launched the industry’s first full set of capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, Benchling’s new RNA solution is the first purpose-built offering on the market to help R&D organizations accelerate the delivery of drug candidates. Featuring an RNA-aware registry with visualization tools for oligo and mRNA design and the only tool with support for chemical modification of mRNA sequences, RNA biologists and chemists can now collaborate more efficiently, standardize their work across teams, and develop drug candidates faster. Following the successful deployment of RNA technology in the Pfizer-BioNTech and Moderna Covid-19 vaccines, biopharma companies have quickly shifted their pipelines to uncover therapeutic opportunities with RNA and mRNA. RNA therapeutics include a diverse group of therapeutic molecules that range from mRNA vaccines to antisense oligos, RNA-based gene therapy, and guide RNA-based CRISPR complexes. The unique function of these molecules, combined with the ability to adjust key properties through chemical modification or conjugation, has opened up novel ways of treating and preventing diseases. Nearly half (44%) of top 50 global biopharma companies are involved in RNA work through their own pipelines, M&A, or strategic alliances, based on GlobalData research. Venture capital has also invested $3 billion into RNA-based therapies in 2020 alone, according to Nature . While RNA therapeutics hold tremendous potential to impact human health, the R&D tools to create, test, and develop these molecules have been severely limited. Traditional chemistry tools cannot model the intricacies of RNA biology, while biology tools ignore the chemistry involved with RNA modifications altogether. As a result, there has not been a single software solution to date that addresses the combined biological and chemical nature of RNA therapeutics. Scientists have had to contend with manual, low-throughput, and disconnected software to manage their R&D work. Meanwhile, 82% of the pipeline of disclosed RNA and nucleotide therapeutics is in the research or preclinical stage of development. “We’re at a tipping point for RNA therapeutics, having figured out tough challenges like durability and stability, the industry is now looking for the right tools to accelerate RNA R&D,” said Ashu Singhal, co-founder and president of Benchling. “Covid vaccines were really just the beginning –- as we put more tools in the hands of scientists to help support their RNA therapeutics R&D, this field will really take off. With Benchling’s new RNA capabilities, scientists can now design, develop, and test a new mRNA vaccine or RNA cancer treatment from start to finish on a single platform.”   "RNA has nearly unlimited potential to cure a wide range of diseases. Benchling's full set of purpose-built tools for RNA therapy development is going to enable us to realize this potential at an even greater pace than before," said Francois Vigneault, co-founder and CEO of Shape Therapeutics, an RNA technology company advancing programmable medicine and a longtime Benchling customer. "We are excited to see Benchling's continued investment in RNA innovation, and appreciate their commitment to helping companies like ShapeTX accelerate next-generation biopharma solutions."   Benchling’s complete RNA solution is available today, and scientists working in RNA and mRNA therapeutics, RNA-based gene therapy, and gene editing will benefit from:    Faster RNA design. Scientists can design RNA sequences more efficiently with easy navigation between monomer- and sequence-level views. They can use “find and replace” to execute chemical modifications more easily across entire sequences and reduce the need for manual, tedious effort. Benchling’s design tool helps scientists standardize their design work, minimize errors, and ensure sequence uniqueness during registration. Simplified collaboration. All teams across the entire RNA R&D lifecycle can now operate on a single platform. With a full end-to-end solution, teams working on RNA across biology and chemistry in both research and development can share, search, and find their work output. This reduces the need for multiple handoffs and back-and-forth communication. Higher quality data and insights. Scientists can now standardize and improve accuracy of RNA sequence design, including management of chemical modifications and uniqueness checks during registration. The standardization and centralization ensure high data integrity and improve data traceability. Any changes in structure can be directly associated with experimental results. As a result, scientists can aggregate data faster and make more data-driven decisions easily. Along with the general availability launch of the RNA full solution, Benchling is making additional new product features generally available, including:   Updated sequence design and analysis: Scientists can design and analyze DNA, RNA, and amino acid sequences with intelligent tools that boost throughput and reduce manual work to support research. With updated DNA alignments, Benchling now supports more algorithms and provides a step-by-step wizard tool to perform a single alignment or many alignments in bulk. Workflows and modern LIMS updates: New features in Benchling’s workflows promote mapping and executing of complex, interconnected activities — from developing, testing, recording, reviewing and approving, to sharing key information with authorized users  — for connected & compliant sample management. New integrations: Benchling now integrates with AlphaFold (a beta feature) that allows users to generate, interact with, and share 3D protein structures of novel proteins. In addition, Benchling is now directly integrated with genome database Ensembl and customers now pull all genomic sequences and data directly from Ensembl’s APIs. Benchling’s mission is to unlock the power of biotechnology by creating modern software for modern science that empowers R&D teams to focus more time on science (not their software)! To learn more about Benchling and these new capabilities, please visit the company’s What’s New page . About Benchling Benchling is the pioneer of the R&D Cloud , software that unlocks the power of biotechnology. More than 200,000 scientists at over 1,000 companies and 7,500 academic and research institutions globally have adopted the Benchling R&D Cloud to make breakthrough discoveries and bring the next generation of medicines, food, and materials to market faster. The Benchling R&D Cloud helps these organizations modernize their scientific processes and accelerate collaboration so they can convert the complexity of biology into world-changing results. For more, please visit or follow us on Twitter at @Benchling . Contact: press@benchling

Benchling Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Benchling Rank

  • When was Benchling founded?

    Benchling was founded in 2012.

  • Where is Benchling's headquarters?

    Benchling's headquarters is located at 680 Folsom St., San Francisco.

  • What is Benchling's latest funding round?

    Benchling's latest funding round is Series F.

  • How much did Benchling raise?

    Benchling raised a total of $412M.

  • Who are the investors of Benchling?

    Investors of Benchling include Altimeter Capital, Franklin Templeton, Lone Pine Capital, Tiger Global Management, Thrive Capital and 26 more.

  • Who are Benchling's competitors?

    Competitors of Benchling include L7 Informatics, BenchSci, Opvia, Synthace, LabArchives, Dotmatics, Uncountable, Labforward, SnapGene, Geneious and 18 more.

  • What products does Benchling offer?

    Benchling's products include Benchling R&D Cloud.

  • Who are Benchling's customers?

    Customers of Benchling include uniQure, Jounce Therapeutics, Beam Therapeutics and Rubius Therapeutics.

You May Also Like

Scilligence Logo

Scilligence provides cross-platform, mobile cheminformatics and bioinformatics software solutions. The company specializes in cheminformatics, Sharepoint and office extension, enterprise search solution, electronic lab notebook, cheminformatics mobile computing, cheminformatics cloud solutions, inventory system for material management, and molecular registration and assay database. It is based in Cambridge, Massachusetts


Jawslab is an easy-to-use and user-friendly Laboratory notebook embedding all the tools to be an ideal companion to scientists' digital transition. By uploading scans of handwritten notes from paper lab notebooks, users can use both paper and electronic lab notebooks to proceed smoothly with the digital transition.

Labforward Logo

Labforward provides a digital laboratory notebook designed to assist in scientific research and study. It is based in Berlin, Germany.


Founded in 2020, ResearchSpace aka RSpace offers an electronic lab notebook that emerged out of the University of Wisconsin.

SciNote Logo

SciNote has developed an Electronic Lab Notebook (ELN) for startups and industry labs, academic labs, GLP and CFR 21 part 11 compliant labs.The company's open source electronic scientific notebook helps you manage your laboratory work and stores all your experimental data in one place. sciNote is specifically designed for life science students, researchers, lab technicians and laboratory managers.

Mestrelab Research Logo
Mestrelab Research

Mestrelab Research is a software development company focused on the development and supply of software for analytical chemistry and analytical chemistry data management. Mestrelab Research develops and markets Mnova, which is used by chemists in both adcademia and industrial environments. Its product, Mbook, is an electronic laboratory notebook.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.